Company news

Elutia, Inc. news in 2024

Elutia, Inc.'s news releases, calls and decks from 2024, newest first.

View company

Elutia Awarded Cardiac Rhythm Management Devices Agreement with Premier, Inc.

December 1, 2024

Elutia Announces Strong Third Quarter Results, Accelerating Toward Full Launch of EluPro® Antibiotic-Eluting BioEnvelope in 2025

November 13, 2024

Elutia to Report Third Quarter 2024 Financial Results on Thursday, November 14, 2024

October 28, 2024

Elutia to Present at the LD Micro Main Event XVII Conference on Wednesday, October 30

October 22, 2024

Elutia Announces New Peer Reviewed Publication Highlighting the Robustness of EluPro™, Company’s Antibiotic-Eluting BioEnvelope for Implantable Devices

September 17, 2024

Elutia Announces First Patient Implant of EluPro™, the World’s First Drug-Eluting BioEnvelope for Cardiac Pacemakers and Neurostimulators

September 4, 2024

Elutia Announces Second Quarter 2024 Results

August 6, 2024

Elutia Announces Full Exercise of Warrants Generating $15.7 Million in Gross Proceeds

July 31, 2024

Elutia Appoints Ryan Marques, Ph.D., MBA as Vice President of Operations

July 30, 2024

Elutia Announces FDA Clearance of EluPro®: The First Antibiotic-Eluting BioEnvelope Designed to Protect Patients with Implantable Cardiac Pacemakers and Defibrillators

June 16, 2024

Elutia Announces $13.26 Million Registered Direct Offering

June 16, 2024

Elutia Announces First Quarter 2024 Results: SimpliDerm® Sales Increase 55%, CanGaroo®RM on Track for Second Quarter 2024 FDA Clearance

May 8, 2024

Elutia to Report First Quarter 2024 Financial Results on Thursday, May 9, 2024

May 1, 2024

Elutia Reports Fourth Quarter and Full Year 2023 Financial Results: Anticipates CanGarooRM® Clearance Decision in First Half of 2024

March 6, 2024

Elutia's CanGarooRM: Pioneering Drug-Eluting Biologic for Secure Medical Implants

February 19, 2024

Calls in 2024

Decks in 2024